• Product NameRecombinant Rat Heparin-binding EGF-like Growth Factor
• Host SpeciesEscherichia coli.
• Purification> 95 % by SDS-PAGE and HPLC analyses.
• Biological ActivityFully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 1 ng/ml, corresponding to a specific activity of > 1.0 x10⁶ IU/mg.
• EndotoxinLess than 1 EU/ug of rRtHB-EGF as determined by LAL method.
• Alternative Names    HBEGF, DT-R
• UniprotQ06175
• Gene ID25433
• Calculated MW Approximately 9.7 kDa, a single non-glycosylated polypeptide chain containing 86 amino acids.
• Target Sequence DLEGTDLDLF KVAFSSKPQA LATPGKEKNG KKKRKGKGLG KKRDPCLKKY KDYCIHGECR YLKELRIPSC HCLPGYHGQR CHGLTL
• Formulation Lyophilized from a 0.2 μm filtered concentrated solution in PBS, 300 mM NaCl, pH 7.4, 5 % trehalose.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70 ˚C under sterile conditions after reconstitution.

Heparin-binding epidermal growth factor (HB-EGF)-like growth factor (EGF) is found in cerebral neurons. Its expression is increased after hypoxic or ischemic injury, which also stimulates neurogenesis. HB-EGF has been implicated as a participant in a variety of normal physiological processes such as blastocyst implantation and wound healing, and in pathological processes such as tumor growth, SMC hyperplasia and atherosclerosis. HB-EGF is an 87 amino acid mitogenic and chemotactic glycoprotein containing an EGF-like domain with six conserved cysteine residues. Rat HB-EGF shares about 76 % a.a. sequence identity with human HB-EGF.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting